SEARCH

SEARCH BY CITATION

References

  • 1
    British Heart Foundation. Heart statistics. http://www.bhf.org.uk/research/heart-statistics.aspx (accessed 14 November 2012).
  • 2
    Nichols M, Townsend N, Scarborough P et al. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
  • 3
    Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 13225.
  • 4
    General Medical Services – contractural changes 2013/2014. http://www.dh.gov.uk/health/2012/12/gp-contract-proposals/ (accessed 19 February 2013).
  • 5
    British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2): S129.
  • 6
    British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 7058.
  • 7
    British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. 5): v152.
  • 8
    National Institute for Health and Clinical Excellence. NICE Clinical Guideline 67. Lipid Modification: Cardiovascular Risk ASsessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: NICE, 2008.
  • 9
    National Institute for Health and Clinical Excellence. NICE Clinical Guideline 87. Type 2 Diabetes: the Management of Type 2 Diabetes. London: NICE, 2009.
  • 10
    Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 112.
  • 11
    Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 167081.
  • 12
    Ridker PM, Genest J, Boekholdt SM et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010; 376: 3339.
  • 13
    Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 7337.
  • 14
    Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 130110.
  • 15
    Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983; 52: 9B12B.
  • 16
    Sazonov V, Beetsch J, Phatak H et al. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database. Atherosclerosis 2010; 208: 2106.
  • 17
    Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009; 202: 22533.
  • 18
    Jick SS, Kaye JA, Vasilakis-Scaramozza C et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 6869.
  • 19
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 20
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 2938.
  • 21
    Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 67683.
  • 22
    Leiter LA, Lundman P, da Silva PM et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 134351.
  • 23
    Tricoci P, Allen JM, Kramer JM et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301: 83141.
  • 24
    Phatak H, Wentworth C, Burke TA. Lipid testing among patients beginning statin therapy in general practice in the United Kingdom. Value Health 2008; 11: 9338.
  • 25
    Ambegaonkar B, Chirovsky D, Tse HF et al. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong. Adv Ther 2012; 29: 42741.
  • 26
    Khovidhunkit W, Silaruks S, Chaithiraphan V et al. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study. Angiology 2012; 63: 52834.
  • 27
    Pettersson B, Ambegaonkar B, Sazonov V et al. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health 2010; 10: 737.
  • 28
    Gitt AK, Drexel H, Feely J et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012; 19: 22130.
  • 29
    Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 92940.
  • 30
    Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 8008.
  • 31
    University of Oxford Clinical Trial Service Unit. The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study. http://www.thrivestudy.org/(accessed 24 January 2013).
  • 32
    Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 225567.
  • 33
    National Institute for Health and Clinical Excellence. NICE Clinical Guideline 71. Identification and Management of Familial Hypercholesterolaemia. NICE: London, 2008.